According to the NIH, an estimated 21 million adults experienced at least one major depressive episode in 2020. Clinicians understand that female gender, social isolation, and disturbed family environment increase risk, but may not recognize presenting symptoms of depression in …
Clinicians face considerable hurdles when diagnosing and managing narcolepsy and idiopathic hypersomnia (IH), largely due to overlapping symptoms, insufficient formal training in sleep medicine, and limited recognition of associated psychiatric and cardiometabolic comorbidities. Compounding the challenge, some therapeutic agents—most notably …
Metabolic dysfunction-associated steatohepatitis (MASH) is a growing clinical challenge due to its increasing prevalence, complex pathophysiology, and strong association with comorbid conditions such as cardiovascular disease and obesity. Evolving diagnostic criteria, risk stratification tools, and new therapeutic options require health …
GLP-1 receptor agonists (GLP-1 RAs) are a top-tier recommendation for patients with type 2 diabetes (T2D), especially those with concomitant cardiovascular disease (CVD), chronic kidney disease (CKD), or obesity. Backed by robust clinical trial data and endorsed across leading guidelines, …
Mycophenolate-containing medications are widely used to prevent organ rejection in transplant recipients and to treat (off label) some autoimmune conditions such as lupus; however, use of these immunosuppressive agents during pregnancy is linked to a significantly increased risk of miscarriage …
